SG11201601047SA - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents - Google Patents
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agentsInfo
- Publication number
- SG11201601047SA SG11201601047SA SG11201601047SA SG11201601047SA SG11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA
- Authority
- SG
- Singapore
- Prior art keywords
- uncialamycin
- synthesis
- derivatives
- methods
- antitumor agents
- Prior art date
Links
- OBGWIHKWGGEOEV-WJPOXRCESA-N (1S,17S,20Z,24R,26R)-4,24-dihydroxy-26-[(1R)-1-hydroxyethyl]-25-oxa-16-azahexacyclo[15.7.2.01,26.02,15.05,14.07,12]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione Chemical class O[C@@H]1C#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C3)=C3[C@@]31O[C@]32[C@H](O)C OBGWIHKWGGEOEV-WJPOXRCESA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865896P | 2013-08-14 | 2013-08-14 | |
US201361868783P | 2013-08-22 | 2013-08-22 | |
US201461937003P | 2014-02-07 | 2014-02-07 | |
PCT/US2014/051127 WO2015023879A1 (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601047SA true SG11201601047SA (en) | 2016-03-30 |
Family
ID=51453866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601047SA SG11201601047SA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
SG10201810067YA SG10201810067YA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201810067YA SG10201810067YA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Country Status (13)
Country | Link |
---|---|
US (3) | US9777013B2 (zh) |
EP (1) | EP3033346B1 (zh) |
JP (2) | JP6474404B2 (zh) |
KR (1) | KR20160068738A (zh) |
CN (1) | CN105899515B (zh) |
AU (2) | AU2014306592B2 (zh) |
CA (1) | CA2921401A1 (zh) |
EA (1) | EA201690388A1 (zh) |
ES (1) | ES2769876T3 (zh) |
IL (1) | IL244084B (zh) |
MX (2) | MX368016B (zh) |
SG (2) | SG11201601047SA (zh) |
WO (1) | WO2015023879A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105899515B (zh) | 2013-08-14 | 2020-01-14 | 威廉马歇莱思大学 | uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途 |
CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
JP6951340B2 (ja) * | 2015-09-23 | 2021-10-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | グリピカン−3結合フィブロネクチンベース足場分子 |
US20180362619A1 (en) | 2015-12-21 | 2018-12-20 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
IL278938B1 (en) | 2018-05-29 | 2024-05-01 | Bristol Myers Squibb Co | Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation |
PT3886914T (pt) | 2018-11-30 | 2023-05-05 | Bristol Myers Squibb Co | Anticorpo compreendendo uma extensão c-terminal de cadeia leve contendo glutamina, conjugados do mesmo, e métodos e utilizações |
KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
CN109928981B (zh) * | 2019-04-19 | 2021-06-11 | 长沙天赐生物医药科技有限公司 | 洋浦霉素类似物、制备方法及其应用 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
US11027253B2 (en) | 2019-09-26 | 2021-06-08 | Chevron Phillips Chemical Company Lp | Systems and methods for reducing heat exchanger fouling rate |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
CA2086679A1 (en) * | 1990-07-05 | 1992-01-06 | Hermanus A. M. Verheul | Receptor directed-toxin conjugates |
US5281710A (en) | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
US5162330A (en) | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
CA2054821C (en) | 1990-11-05 | 2001-05-01 | Wilhelm Quittmann | Process for the production of 3-aminocrotononitrile |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
WO1996003124A1 (en) * | 1994-07-27 | 1996-02-08 | California Institute Of Technology | Dynemicin analogs |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US8507445B2 (en) | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
MXPA04006490A (es) | 2002-01-09 | 2005-06-08 | Medarex Inc | Anticuerpos monoclonales humanos contra cd30. |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
KR101215218B1 (ko) | 2003-07-22 | 2012-12-26 | 바이엘 파마 악티엔게젤샤프트 | Rg1 항체 및 그의 용도 |
WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
AU2005244980B2 (en) | 2004-05-19 | 2011-09-15 | E. R. Squibb & Sons, L.L.C. | Chemical linkers and conjugates thereof |
US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
ES2386366T3 (es) | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
EP1851251A2 (en) | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
WO2007038637A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
WO2007067730A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
AU2007222991A1 (en) | 2006-03-09 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Compositions and methods based on peptide binding profiling |
MX2008015132A (es) | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
CA2657811C (en) | 2006-06-29 | 2014-10-21 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
AU2007292891B2 (en) | 2006-09-08 | 2012-04-12 | Ambrx, Inc. | Site specific incorporation of non-natural amino acids by vertebrate cells |
JP5398538B2 (ja) | 2006-12-01 | 2014-01-29 | メダレックス・リミテッド・ライアビリティ・カンパニー | Cd22に結合するヒト抗体およびその使用 |
MX2009006277A (es) | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
WO2009012394A1 (en) | 2007-07-17 | 2009-01-22 | Medarex, Inc. | Monoclonal antibodies against glypican-3 |
EA018396B1 (ru) | 2007-10-01 | 2013-07-30 | Бристоль-Мейерз Сквибб Компани | Антитела человека, которые связывают мезотелин, и применение таких антител |
EP2653543A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and Compositions |
US8450278B2 (en) | 2008-10-15 | 2013-05-28 | Board Of Regents, The University Of Texas System | MUC18 targeting peptides |
US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
AR089972A1 (es) | 2012-02-13 | 2014-10-01 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de estos y sus usos y metodos |
US8798431B2 (en) | 2012-06-01 | 2014-08-05 | Telefonaktiebolaget L M Ericsson (Publ) | Fine-grained optical shuffle interconnect topology migration |
CN105899515B (zh) | 2013-08-14 | 2020-01-14 | 威廉马歇莱思大学 | uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途 |
-
2014
- 2014-08-14 CN CN201480056718.0A patent/CN105899515B/zh active Active
- 2014-08-14 MX MX2016001975A patent/MX368016B/es active IP Right Grant
- 2014-08-14 WO PCT/US2014/051127 patent/WO2015023879A1/en active Application Filing
- 2014-08-14 AU AU2014306592A patent/AU2014306592B2/en not_active Ceased
- 2014-08-14 KR KR1020167006599A patent/KR20160068738A/ko not_active Application Discontinuation
- 2014-08-14 JP JP2016534843A patent/JP6474404B2/ja active Active
- 2014-08-14 EP EP14758223.3A patent/EP3033346B1/en active Active
- 2014-08-14 EA EA201690388A patent/EA201690388A1/ru unknown
- 2014-08-14 SG SG11201601047SA patent/SG11201601047SA/en unknown
- 2014-08-14 ES ES14758223T patent/ES2769876T3/es active Active
- 2014-08-14 CA CA2921401A patent/CA2921401A1/en not_active Abandoned
- 2014-08-14 SG SG10201810067YA patent/SG10201810067YA/en unknown
- 2014-08-14 US US14/911,881 patent/US9777013B2/en active Active
-
2016
- 2016-02-11 IL IL244084A patent/IL244084B/en not_active IP Right Cessation
- 2016-02-12 MX MX2019010875A patent/MX2019010875A/es unknown
-
2017
- 2017-08-15 US US15/677,959 patent/US10233192B2/en active Active
-
2019
- 2019-01-29 JP JP2019013008A patent/JP2019089804A/ja active Pending
- 2019-03-18 US US16/357,109 patent/US10889590B2/en active Active
- 2019-06-07 AU AU2019204034A patent/AU2019204034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9777013B2 (en) | 2017-10-03 |
KR20160068738A (ko) | 2016-06-15 |
EP3033346A1 (en) | 2016-06-22 |
CN105899515B (zh) | 2020-01-14 |
US10233192B2 (en) | 2019-03-19 |
CN105899515A (zh) | 2016-08-24 |
JP6474404B2 (ja) | 2019-02-27 |
JP2019089804A (ja) | 2019-06-13 |
MX2016001975A (es) | 2016-11-14 |
MX368016B (es) | 2019-09-13 |
JP2016534105A (ja) | 2016-11-04 |
ES2769876T3 (es) | 2020-06-29 |
US20180065976A1 (en) | 2018-03-08 |
AU2014306592B2 (en) | 2019-04-04 |
US10889590B2 (en) | 2021-01-12 |
EP3033346B1 (en) | 2020-01-08 |
WO2015023879A1 (en) | 2015-02-19 |
CA2921401A1 (en) | 2015-02-19 |
US20190382412A1 (en) | 2019-12-19 |
US20160185791A1 (en) | 2016-06-30 |
AU2019204034A1 (en) | 2019-07-04 |
MX2019010875A (es) | 2019-12-19 |
AU2014306592A1 (en) | 2016-03-10 |
IL244084A0 (en) | 2016-04-21 |
SG10201810067YA (en) | 2018-12-28 |
IL244084B (en) | 2019-08-29 |
EA201690388A1 (ru) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170919T1 (hr) | Novi derivati pirazola | |
SG11201505309TA (en) | Benzylamine derivatives | |
SG11201601047SA (en) | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | |
GB201421334D0 (en) | Synthesis of aeizeolite | |
HRP20181710T1 (hr) | Uporaba derivata benzimidazol-prolina | |
HK1215574A1 (zh) | 作為 -配體的二氮雜哢唑衍生物 | |
ZA201602198B (en) | Preparation of hydroxy-benzylbenzene derivatives | |
SG11201602579SA (en) | Bicyclic alkyne derivatives and uses thereof | |
HK1220456A1 (zh) | -乙酰嗎啡類似物,和其合成方法和用途 | |
PL3055307T3 (pl) | Podstawione berbiny i ich synteza | |
EP2958947A4 (en) | CONJUGATE CONNECTION AND USES THEREOF | |
HK1216099A1 (zh) | 苄胺衍生物 | |
PT3010896T (pt) | Derivados inovadores de amidino-ureia macrocíclicos, métodos de preparação e utilizações dos mesmos como inibidores de quitinase | |
EP2870133A4 (en) | TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF | |
IL244411A0 (en) | A procedure for the synthesis of derivatives of n-benzyl-n-cyclopropyl-1h-pyrazole-4-carboxamide | |
EP3006451A4 (en) | ARBEKACINE DERIVATIVES AND THE PREPARATION AND USE THEREOF | |
TH1401003816A (th) | องค์ประกอบ, การสังเคราะห์, และ วิธีการของการใช้อนุพันธ์ฟีนิลไซโคลอัลคิลเมทธิลเอมีน | |
AU2013900781A0 (en) | Nacre-like composites, methods of synthesis and methods of use | |
GB201310660D0 (en) | Synthesis of nucleosides |